Lydia Scarfò

Assistant Professor
Università Vita Salute and IRCCS Ospedale San Raffaele, Italy

N/A

Poster(s):

• 1014 - Highlighting a crucial role for EGR2 mutations in CLL pathogenesis and BTKi resistance

• 1016 - Integrating phosphoproteomic analysis and innovative 3D cell culture systems to dissect the role of extracellular stiffness in CLL pathogenesis

• 1107 - Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation

• 1207 - In vitro investigation of the phenotype of CLL cells during trafficking and homing in a 3D-printed bioreactor

• 1402 - Cytogenetic instability and therapeutic pressure in Fixed vs Continuous regimens for Chronic Lymphocytic Leukemia after first line treatment: Preliminary Data from an Italian Multicenter Experience

• 1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL

• 1435 - Absence of lymphocytosis after starting treatment with cBTKi is a rare phenomenon except for trisomy 12 and CD49d positive CLL

• 1438 - Central Nervous System Involvement in Chronic Lymphocytic Leukemia: An International Retrospective Study by ERIC, the European Research Initiative on CLL

• 1525 - Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study

• 1706 - A Qualitative Study to Explore the Patient Experience of Continuous Covalent Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Study Methodology

• 1709 - Impact of Dose Intensity of Ibrutinib on Clinical Outcomes of CLL Patients: Analysis of the EVIdeNCE Study

• 1902 - Impact of treatment with ibrutinib or venetoclax on CAR-T cell generation in patients with chronic lymphocytic leukemia. Interim analysis of the GIMEMA CLL2020 study

• 1907 - Autoimmune cytopenias in patients with chronic lymphocytic leukemia receiving acalabrutinib treatment.